In Vitro Activity of Telavancin against Gram-Positive Clinical Isolates Recently Obtained in Europe
- 1 September 2007
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 51 (9) , 3420-3424
- https://doi.org/10.1128/aac.00100-07
Abstract
The in vitro activity of telavancin was tested against 620 gram-positive isolates. For staphylococci, MICs at which 50 and 90% of isolates were inhibited (MIC 50 and MIC 90 ) were both 0.25 μg/ml, irrespective of methicillin resistance. MIC 50 and MIC 90 were 0.25 and 0.5 μg/ml for vancomycin-susceptible enterococci and 1 and 2 μg/ml for vancomycin-resistant enterococci, respectively. Streptococcus pneumoniae , group A and B beta-hemolytic streptococci, and viridans streptococci were inhibited by ≤0.12 μg/ml.Keywords
This publication has 10 references indexed in Scilit:
- Comparative activity of the new lipoglycopeptide telavancin in the presence and absence of serum against 50 glycopeptide non-susceptible staphylococci and three vancomycin-resistant Staphylococcus aureusJournal of Antimicrobial Chemotherapy, 2006
- Telavancin versus Standard Therapy for Treatment of Complicated Skin and Skin Structure Infections Caused by Gram-Positive Bacteria: FAST 2 StudyAntimicrobial Agents and Chemotherapy, 2006
- Recent developments in glycopeptide antibacterials.2005
- Telavancin Versus Standard Therapy for Treatment of Complicated Skin and Soft-Tissue Infections Due to Gram-Positive BacteriaClinical Infectious Diseases, 2005
- Telavancin, a Multifunctional Lipoglycopeptide, Disrupts both Cell Wall Synthesis and Cell Membrane Integrity in Methicillin-Resistant Staphylococcus aureusAntimicrobial Agents and Chemotherapy, 2005
- Pharmacokinetics, Serum Inhibitory and Bactericidal Activity, and Safety of Telavancin in Healthy SubjectsAntimicrobial Agents and Chemotherapy, 2005
- Glycopeptides in clinical development: pharmacological profile and clinical perspectivesCurrent Opinion in Pharmacology, 2004
- In Vitro Activities of the New Semisynthetic Glycopeptide Telavancin (TD-6424), Vancomycin, Daptomycin, Linezolid, and Four Comparator Agents against Anaerobic Gram-Positive Species and Corynebacterium sppAntimicrobial Agents and Chemotherapy, 2004
- Comparative in vitro activity of telavancin (TD-6424), a rapidly bactericidal, concentration-dependent anti-infective with multiple mechanisms of action against Gram-positive bacteriaJournal of Antimicrobial Chemotherapy, 2004
- In Vitro Activity of TD-6424 againstStaphylococcus aureusAntimicrobial Agents and Chemotherapy, 2003